Abstract
The aim of the present paper is to highlight that new variants, either of higher viral load such as delta or higher contagiousness like omicron, lead to an even higher airborne transmission than historical strains. We first review the question of the route of contamination and of the dose following exposure, and the importance of the counting unit for pathogens, itself linked to the dose-response law. Using the counting unit of Wells, i.e. the quantum of contagium, we develop the conservation equation of quanta which allows deriving the value of the quantum concentration at steady state for a well-mixed room. With the choice of an exponential response function, this leads to the famous Wells-Riley equation. The analysis points out the importance of a number of parameters such as the time of exposure, the quantum production rate, mask wearing and the incidence rate in the population in order to evaluate the risk. The link with the monitoring concentration of carbon dioxide is made and used for a risk analysis of a variety of situations for which we have made concrete CO2 time monitoring. The main conclusion of these observations is that the present norms of ventilation, already insufficient, are not respected, especially in a variety of public premises, leading to high risk of contamination. Finally, we insist that public health policy in the field of airborne transmission should be based on a multi parameter analysis, considering the whole complexity of dose evaluation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
